“These are real people facing their mortality with no hope,” Senator Ron Johnson (R-WI), who sponsored the bill, said from the Senate floor. “This right-to-try piece of legislation will give those individuals and their family hope.”
The current bill is an updated version of legislation that Johnson proposed in January, and was passed as part of a deal after the Senator threatened to delay a critical FDA funding reauthorization bill unless a vote took place on the right-to-try legislation. Unlike the original version, the now-passed legislation requires that safety problems occurring in right-to-try situations are reported to the FDA. It also prevents drug companies from charging patients more than the production cost for the treatment itself.
Critics argue that the measure is unnecessary, as the FDA approves more than 90 percent of requests for compassionate use of experimental treatments, and it is the drug companies that are reluctant to supply patients with unapproved products. NYU Langone Medical Center’s Alison Bateman-House, an assistant professor of medical ethics, tells the Washington Post that the bill is consequently “inherently deceptive.”
Meanwhile, the consumer group Public Citizen warns that the move could be problematic for the FDA, undermining the agency’s authority in the approval procedure for experimental treatments, the New York Times reports—all the while, providing “false hope to patients.”